An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 1236 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 21 Nov 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Nov 2009 New trial record